GlobeNewswire Clinical StudiesOriginal article
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry’s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed/Refractory B Cell Malignancies
RegulatoryapprovedUB-VV400Positive
AI Analysis
Summary
Umoja Biopharma announced FDA clearance of its IND application for UB-VV400, described as the industry's first known CD22-directed in vivo CAR T cell therapy for relapsed/refractory B cell malignancies in adults. The clearance allows the company to initiate clinical trials for this novel immunotherapy candidate.
Outcome Details
FDA cleared IND application for UB-VV400, a CD22-directed in vivo CAR T cell therapy
Importance:7/10
Sentiment:
0.85
CAR-T therapyimmunotherapyCD22-directedin vivoB cell malignanciesIND clearance
Read the original article
Published by GlobeNewswire Clinical Studies on July 16, 2026 12:00 PM